The nonprofit will look to support grass-roots organizations that are part of a progressive movement against President Trump’s policies.
NYS Entity Status
NYS Filing Date
JUNE 13, 2013
NYS DOS ID#
108-27 66 AVE
FOREST HILLS, NEW YORK, 11375
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - ONWARD DEVELOPMENT GROUP INC.
Around the Web
- Hillary Clinton Starts Onward Together, a New Political Group
By NIRAJ CHOKSHI - Tuesday May 16, 2017
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Listing of the Day: Toronto Forest Hill
Friday Jun 23, 2017
The sprawling steel-frame and concrete mansion sits in Toronto's most prestigious and affluent neighborhoods.
- IAB Tech Lab Launches Blockchain Working Group
Monday Sep 18, 2017
GroupM, Kochava, MetaX, and Nyiax have become member companies in an IAB Tech Lab working group that launched Monday focused on blockchain and explore ways to use it in digital technology. ShailleySingh leads the group. The working group will initially design ways to educate the industry, set priorities for business use cases and develop standards and best practices.
- Solar Developers and Panel Makers Clash Over Tariff Request
By DIANE CARDWELL - Tuesday Aug 15, 2017
Troubled domestic manufacturers say cheap Chinese products have undercut their own, but industry groups are urging a trade panel to reject sanctions.
- Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
By Caroline Chen - Tuesday Oct 17, 2017
Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.